Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1980 May;40(2):249–255.

A novel eosinophil chemotactic factor derived from a histiocytic lymphoma of the central nervous system.

E J Goetzl, J Rothenberg, E L Weber, C M Sinn, K F Austen
PMCID: PMC1536990  PMID: 7438536

Abstract

An eosinophil chemotactic activity was identified in extracts of tumour tissue and cerebrospinal fluid from a patient with a histiocytic lymphoma of the brain and spinal cord that was infiltrated extensively with eosinophils and associated with peripheral blood eosinophilia. The histiocytic lymphoma-derived eosinophils chemotactic factor, termed ECF-HL, exhibited a mol. wt of 13,000-14,000 by filtration on Sephadex G-50, was highly acidic based on its elution from a high pressure anion exchange column at pH 2 x 3 - 2 x 1, and was susceptible to inactivation by proteolytic digestion. ECF-HL was absent from extracts of control human brain tissue, glioblastomas, other lymphomas and a variety of carcinomas that lacked an accumulation of eosinophils. Partially purified ECF-HL had no chemokinetic activity, but rendered eosinophils unresponsive to other chemotactic factors. Thus ECF-HL is structurally and functionally distinct from other recognized peptides that are preferentially chemotactic for eosinophils.

Full text

PDF
250

Images in this article

252Fig. 1
on p.252

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barth R. F., Vergara G. G., Khurana S. K., Lowman J. T., Beckwith J. B. Rapidly fatal familial histiocytosis associated with eosinophilia and primary immunological deficiency. Lancet. 1972 Sep 9;2(7776):503–506. doi: 10.1016/s0140-6736(72)91904-6. [DOI] [PubMed] [Google Scholar]
  2. Boswell R. N., Austen K. F., Goetzl E. J. Intermediate molecular weight eosinophil chemotactic factors in rat peritoneal mast cells: immunologic release, granule association, and demostration of structura heterogeneity. J Immunol. 1978 Jan;120(1):15–20. [PubMed] [Google Scholar]
  3. Goetzl E. J., Austen K. F. Purification and synthesis of eosinophilotactic tetrapeptides of human lung tissue: identification as eosinophil chemotactic factor of anaphylaxis. Proc Natl Acad Sci U S A. 1975 Oct;72(10):4123–4127. doi: 10.1073/pnas.72.10.4123. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Goetzl E. J., Austen K. F. Structural determinants of the eosinophil: chemotactic activity of the acidic tetrapeptides of eosinophil chemotactic factor of anaphylaxis. J Exp Med. 1976 Dec 1;144(6):1424–1437. doi: 10.1084/jem.144.6.1424. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Goetzl E. J., Gorman R. R. Chemotactic and chemokinetic stimulation of human eosinophil and neutrophil polymorphonuclear leukocytes by 12-L-hydroxy-5,8,10-heptadecatrienoic acid (HHT). J Immunol. 1978 Feb;120(2):526–531. [PubMed] [Google Scholar]
  6. Goetzl E. J., Hoe K. Y. Chemotactic factor receptors of human PMN leucocytes. I. Effects on migration of labelling plasma membrane determinants with impermeant covalent reagents and inhibition of labelling by chemotactic factors. Immunology. 1979 Jun;37(2):407–418. [PMC free article] [PubMed] [Google Scholar]
  7. Goetzl E. J., Tashjian A. H., Jr, Rubin R. H., Austen K. F. Production of a low molecular weight eosinophil polymorphonuclear leukocyte chemotactic factor by anaplastic squamous cell carcinomas of human lung. J Clin Invest. 1978 Mar;61(3):770–780. doi: 10.1172/JCI108991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Henderson A. H., Mejia G. Malignant lymphoma presenting with a high eosinophilia, eosinophilic pleurisy, and pericrditis. Thorax. 1969 Jan;24(1):124–125. doi: 10.1136/thx.24.1.124. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Kay A. B., McVie J. M., Stuart A. E., Krajewski A., Turnbull L. W. Eosinophil chemotaxis of supernatants from cultured Hodgkin's lymph node cells. J Clin Pathol. 1975 Jun;28(6):502–505. doi: 10.1136/jcp.28.6.502. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Liao K. T., Rosai J., Daneshbod K. Malignant histiocytosis with cutaneous involvement and eosinophilia. Am J Clin Pathol. 1972 Apr;57(4):438–448. doi: 10.1093/ajcp/57.4.438. [DOI] [PubMed] [Google Scholar]
  11. Muggia F. M., Ghossein N. A., Wohl H. Eosinophilia following radiation therapy. Oncology. 1973;27(2):118–127. doi: 10.1159/000224727. [DOI] [PubMed] [Google Scholar]
  12. Viola M. V., Chung E., Mukhopadhyay M. G. Eosinophila and metastatic carcinoma. Med Ann Dist Columbia. 1972 Jan;41(1):1–3. [PubMed] [Google Scholar]
  13. Wasserman S. I., Goetzl E. J., Austen K. F. Preformed eosinophil chemotactic factor of anaphylaxis (ECF-A). J Immunol. 1974 Jan;112(1):351–358. [PubMed] [Google Scholar]
  14. Wasserman S. I., Goetzl E. J., Ellman L., Austen K. F. Tumor-associated eosinophilotactic factor. N Engl J Med. 1974 Feb 21;290(8):420–424. doi: 10.1056/NEJM197402212900802. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES